3 Overrated Stocks That Concern Us

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

However, not all companies with momentum are long-term winners, and many investors have lost money by following short-term trends. On that note, here are three stocks getting more buzz than they deserve and some you should buy instead.

Vishay Intertechnology (VSH)

One-Month Return: +22%

Named after the founder's ancestral village in present-day Lithuania, Vishay Intertechnology (NYSE:VSH) manufactures simple chips and electronic components that are building blocks of virtually all types of electronic devices.

Why Do We Think VSH Will Underperform?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 5% annually over the last two years
2. High input costs result in an inferior gross margin of 20.3% that must be offset through higher volumes
3. Long-term business health is up for debate as its cash burn has increased over the last five years

Vishay Intertechnology’s stock price of $19.52 implies a valuation ratio of 34.5x forward P/E. To fully understand why you should be careful with VSH, check out our full research report (it’s free).

Pangaea (PANL)

One-Month Return: +24.2%

Established in 1996, Pangaea Logistics (NASDAQ:PANL) specializes in global logistics and transportation services, focusing on the shipment of dry bulk cargoes.

Why Does PANL Give Us Pause?

1. High input costs result in an inferior gross margin of 19.1% that must be offset through higher volumes
2. Earnings per share have contracted by 33.6% annually over the last four years, a headwind for returns as stock prices often echo long-term EPS performance
3. Poor free cash flow margin of 0.6% for the last five years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends

At $8.45 per share, Pangaea trades at 8.7x forward P/E. If you’re considering PANL for your portfolio, see our FREE research report to learn more.

Gilead Sciences (GILD)

One-Month Return: +24.4%

From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ:GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.

Why Are We Wary of GILD?

1. Annual sales growth of 3.6% over the last five years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand
2. 7.5 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
3. Diminishing returns on capital suggest its earlier profit pools are drying up

Gilead Sciences is trading at $151.48 per share, or 17.9x forward P/E. Read our free research report to see why you should think twice about including GILD in your portfolio.

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.